Trading

Data

Solutions

Insights

RxSight Stock

rxsight.comHealthcareFunding to Date: $179.84MM

RxSight is the developer of the first and only adjustable intraocular lens (IOL) that is customized after cataract surgery, enabling doctors and patients to predictably optimize vision after cataract surgery through an office based IOL enhancement.

Learn more about RxSight IPO

Overview Financings Valuation

Enterprise Value (based on primary financings)

View Enterprise Value for RxSight.

Register Today

Team

Management Team

Shelley Thunen

Chief Financial Officer

Robert Grubbs

Co-Founder

Ronald Kurtz MD

Chief Executive Officer, President & Board Member

Christian Sandstedt Ph.D

Vice President, Optics Research & Development

Matthew Haller Ph.D

Chief Technology Officer

Eric Weinberg

Chief Commercial Officer

Board Members

Christopher Cox JD

Werner Wolfen

Javier Perez-Sala

Bruce Robertson Ph.D

H.I.G. BioHealth Partners

J. Corley

Ronald Kurtz MD

Juliet Bakker

Longitude Capital

Jan Bonel

Daniel Schwartz

William Link Ph.D

Flying L Partners

Joseph Devivo

James Adler

Other companies like RxSight in the Healthcare sector

Neuralink

Sector

Healthcare

Last Round Est. Valuation

$2.15B

Sector

Sector

Last Round Est. Valuation

$3.67B

Synchron

Sector

Healthcare

Last Round Est. Valuation

$400.53MM

Grail

Sector

Healthcare

Last Round Est. Valuation

$4.26B

Sector

Sector

Sector

Last Round Est. Valuation

$1.08B

Precision Neuroscience

Sector

Healthcare

News

The Wall Street Journal 06/04/2015

Calhoun Vision Raises $69M, Advances Novel Lenses for Cataract Patients

Venture investors are providing $69 million to Calhoun Vision Inc. and betting that its technology will make it stand out in a crowded market for artificial lenses used in cataract patients.

Popular Topics

Popular Topics

RxSight Stock

Register for Details